• Explore /
  • Poster
  • / TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.

TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.

Abstract Poster

Authors

null

Mark Christopher Markowski

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Mark Christopher Markowski , Cora N. Sternberg , Hao Wang , Rana Sullivan , Serina King , Tamara L. Lotan , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03413995

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 190)

DOI

10.1200/JCO.2023.41.6_suppl.190

Abstract #

190

Poster Bd #

G5

Abstract Disclosures

Similar Posters

First Author: Mark Christopher Markowski

First Author: Kamal Kant Kant Sahu

First Author: E. Gabriela Chiorean

First Author: Elias Chandran